239 related articles for article (PubMed ID: 20406946)
1. X-linked inhibitor of apoptosis protein inhibits apoptosis in inflammatory breast cancer cells with acquired resistance to an ErbB1/2 tyrosine kinase inhibitor.
Aird KM; Ghanayem RB; Peplinski S; Lyerly HK; Devi GR
Mol Cancer Ther; 2010 May; 9(5):1432-42. PubMed ID: 20406946
[TBL] [Abstract][Full Text] [Related]
2. ErbB1/2 tyrosine kinase inhibitor mediates oxidative stress-induced apoptosis in inflammatory breast cancer cells.
Aird KM; Allensworth JL; Batinic-Haberle I; Lyerly HK; Dewhirst MW; Devi GR
Breast Cancer Res Treat; 2012 Feb; 132(1):109-19. PubMed ID: 21559822
[TBL] [Abstract][Full Text] [Related]
3. Trastuzumab signaling in ErbB2-overexpressing inflammatory breast cancer correlates with X-linked inhibitor of apoptosis protein expression.
Aird KM; Ding X; Baras A; Wei J; Morse MA; Clay T; Lyerly HK; Devi GR
Mol Cancer Ther; 2008 Jan; 7(1):38-47. PubMed ID: 18202008
[TBL] [Abstract][Full Text] [Related]
4. XIAP inhibition and generation of reactive oxygen species enhances TRAIL sensitivity in inflammatory breast cancer cells.
Allensworth JL; Aird KM; Aldrich AJ; Batinic-Haberle I; Devi GR
Mol Cancer Ther; 2012 Jul; 11(7):1518-27. PubMed ID: 22508521
[TBL] [Abstract][Full Text] [Related]
5. A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer.
Xia W; Bacus S; Hegde P; Husain I; Strum J; Liu L; Paulazzo G; Lyass L; Trusk P; Hill J; Harris J; Spector NL
Proc Natl Acad Sci U S A; 2006 May; 103(20):7795-800. PubMed ID: 16682622
[TBL] [Abstract][Full Text] [Related]
6. Preclinical assessment of simultaneous targeting of epidermal growth factor receptor (ErbB1) and ErbB2 as a strategy for cholangiocarcinoma therapy.
Zhang Z; Oyesanya RA; Campbell DJ; Almenara JA; Dewitt JL; Sirica AE
Hepatology; 2010 Sep; 52(3):975-86. PubMed ID: 20607690
[TBL] [Abstract][Full Text] [Related]
7. Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells.
Canfield K; Li J; Wilkins OM; Morrison MM; Ung M; Wells W; Williams CR; Liby KT; Vullhorst D; Buonanno A; Hu H; Schiff R; Cook RS; Kurokawa M
Cell Cycle; 2015; 14(4):648-55. PubMed ID: 25590338
[TBL] [Abstract][Full Text] [Related]
8. Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors.
Chen FL; Xia W; Spector NL
Clin Cancer Res; 2008 Nov; 14(21):6730-4. PubMed ID: 18980964
[TBL] [Abstract][Full Text] [Related]
9. X-linked inhibitor of apoptosis protein mediates tumor cell resistance to antibody-dependent cellular cytotoxicity.
Evans MK; Sauer SJ; Nath S; Robinson TJ; Morse MA; Devi GR
Cell Death Dis; 2016 Jan; 7(1):e2073. PubMed ID: 26821068
[TBL] [Abstract][Full Text] [Related]
10. Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism.
Allensworth JL; Sauer SJ; Lyerly HK; Morse MA; Devi GR
Breast Cancer Res Treat; 2013 Jan; 137(2):359-71. PubMed ID: 23225169
[TBL] [Abstract][Full Text] [Related]
11. The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer.
Chu I; Blackwell K; Chen S; Slingerland J
Cancer Res; 2005 Jan; 65(1):18-25. PubMed ID: 15665275
[TBL] [Abstract][Full Text] [Related]
12. Hypoxia/HIF1α induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2.
Karakashev SV; Reginato MJ
Oncotarget; 2015 Feb; 6(4):1967-80. PubMed ID: 25596742
[TBL] [Abstract][Full Text] [Related]
13. Role of X-Linked Inhibitor of Apoptosis as a Prognostic Marker and Therapeutic Target in Papillary Thyroid Carcinoma.
Hussain AR; Bu R; Ahmed M; Jehan Z; Beg S; Al-Sobhi S; Al-Dayel F; Siraj AK; Uddin S; Al-Kuraya KS
J Clin Endocrinol Metab; 2015 Jul; 100(7):E974-85. PubMed ID: 25974735
[TBL] [Abstract][Full Text] [Related]
14. Truncated ErbB2 expressed in tumor cell nuclei contributes to acquired therapeutic resistance to ErbB2 kinase inhibitors.
Xia W; Liu Z; Zong R; Liu L; Zhao S; Bacus SS; Mao Y; He J; Wulfkuhle JD; Petricoin EF; Osada T; Yang XY; Hartman ZC; Clay TM; Blackwell KL; Lyerly HK; Spector NL
Mol Cancer Ther; 2011 Aug; 10(8):1367-74. PubMed ID: 21673090
[TBL] [Abstract][Full Text] [Related]
15. GW583340 and GW2974, human EGFR and HER-2 inhibitors, reverse ABCG2- and ABCB1-mediated drug resistance.
Sodani K; Tiwari AK; Singh S; Patel A; Xiao ZJ; Chen JJ; Sun YL; Talele TT; Chen ZS
Biochem Pharmacol; 2012 Jun; 83(12):1613-22. PubMed ID: 22414725
[TBL] [Abstract][Full Text] [Related]
16. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
[TBL] [Abstract][Full Text] [Related]
17. Quantitative high-throughput efficacy profiling of approved oncology drugs in inflammatory breast cancer models of acquired drug resistance and re-sensitization.
Williams KP; Allensworth JL; Ingram SM; Smith GR; Aldrich AJ; Sexton JZ; Devi GR
Cancer Lett; 2013 Aug; 337(1):77-89. PubMed ID: 23689139
[TBL] [Abstract][Full Text] [Related]
18. An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.
Schwarz LJ; Hutchinson KE; Rexer BN; Estrada MV; Gonzalez Ericsson PI; Sanders ME; Dugger TC; Formisano L; Guerrero-Zotano A; Red-Brewer M; Young CD; Lantto J; Pedersen MW; Kragh M; Horak ID; Arteaga CL
J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059433
[TBL] [Abstract][Full Text] [Related]
19. Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers.
Xia W; Bisi J; Strum J; Liu L; Carrick K; Graham KM; Treece AL; Hardwicke MA; Dush M; Liao Q; Westlund RE; Zhao S; Bacus S; Spector NL
Cancer Res; 2006 Feb; 66(3):1640-7. PubMed ID: 16452223
[TBL] [Abstract][Full Text] [Related]
20. Dual ErbB1 and ErbB2 receptor tyrosine kinase inhibition exerts synergistic effect with conventional chemotherapy in pancreatic cancer.
Singla S; Pippin JA; Drebin JA
Oncol Rep; 2012 Dec; 28(6):2211-6. PubMed ID: 23007710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]